Analyze Diet
Frontiers in veterinary science2022; 9; 979794; doi: 10.3389/fvets.2022.979794

Pharmacokinetics of butorphanol following intravenous and intramuscular administration in donkeys: A preliminary study.

Abstract: The pharmacokinetics of butorphanol after intravenous (IVB) and intramuscular (IMB) administration in donkeys were determined in this preliminary study. Healthy male gelded donkeys ( = 5), aged 6-12 years old, were administered 0.1 mg/kg butorphanol IV or IM in a randomized, crossover design. Blood samples were obtained at predetermined intervals for 24 h (IVB) and 48 h (IMB) after administration. Plasma butorphanol concentrations were determined by high performance liquid chromatography and pharmacokinetic parameters were calculated. Following IVB administration, mean (± SE) apparent volume of distribution, elimination half-life, total body clearance, and area under the plasma concentration time curve from time 0 to infinity (AUC) were 322 ± 50 mL/kg, 0.83 ± 0.318 h, 400 ± 114 mL/h/kg, 370 ± 131 h·ng/mL, respectively. After IMB administration, a maximum plasma drug concentration of 369 ± 190 ng/mL was reached at 0.48 ± 0.09 h. The IMB AUC was 410 ± 60 h·ng/mL. Bioavailability of IMB was 133 ± 45%. The pharmacokinetics of butorphanol in healthy donkeys was characterized by faster elimination half-life compared to values from the equine literature.
Publication Date: 2022-09-23 PubMed ID: 36213418PubMed Central: PMC9539103DOI: 10.3389/fvets.2022.979794Google Scholar: Lookup
The Equine Research Bank provides access to a large database of publicly available scientific literature. Inclusion in the Research Bank does not imply endorsement of study methods or findings by Mad Barn.
  • Journal Article

Summary

This research summary has been generated with artificial intelligence and may contain errors and omissions. Refer to the original study to confirm details provided. Submit correction.

This study investigates the pharmacokinetics of a drug called butorphanol, given intravenously (IV) and intramuscularly (IM) in donkeys, and finds that the drug is eliminated from the body faster than prior studies in horses suggest.

Design of the Research

  • The study examined the pharmacokinetics i.e., how the medicine moves inside the body, of the drug butorphanol in donkeys, following its administration through intravenous and intramuscular routes.
  • The sample group comprised of 5 healthy male donkeys between the ages of 6 to 12 years old.
  • The administration of the drug was randomized, and followed a crossover design, which essentially means each donkey underwent both methods of drug administration, but in a different order, to avoid any potential bias.
  • The quantity of the drug administered was 0.1 mg/kg body weight, so as to maintain uniformity and minimize the impact of weight-related differences among the donkeys.

Data Collection & Analysis

  • Blood samples were taken from the donkeys at specific intervals for 24 hours post administration of intravenous butorphanol (IVB), and for 48 hours post intramuscular butorphanol (IMB) administration.
  • Butorphanol concentration levels were measured using a method called high performance liquid chromatography.
  • Pharmacokinetic parameters were calculated to assess the changes in concentration over time. These parameters included volume of distribution (how well the drug has been distributed throughout the body), elimination half-life, total body clearance (how well the body gets rid of the drug), and area under the curve (a measure of total drug exposure).

Research Findings

  • The findings revealed that post IVB administration, the average volume of distribution, elimination half-life, total body clearance, and area under the plasma concentration time curve were 322 mL/kg, 0.83 hours, 400 mL/h/kg, and 370 h·ng/mL respectively.
  • After IMB administration, maximum plasma drug concentration was 369 ng/mL, which was reached approximately 0.48 hours after administration. The IMB area under the curve was 410 h·ng/mL.
  • The bioavailability (proportion of the drug that enters circulation and have an active effect) of IMB was 133%, suggesting that more drug was absorbed than administered, possibly due to the enterohepatic recirculation.
  • In comparison to previous studies in horses, this study found a faster elimination half-life of butorphanol in donkeys implying the drug is cleared faster in donkeys than in horses.

Cite This Article

APA
Ebner L, O O, Simon B, Lizarraga I, Smith J, Cox S. (2022). Pharmacokinetics of butorphanol following intravenous and intramuscular administration in donkeys: A preliminary study. Front Vet Sci, 9, 979794. https://doi.org/10.3389/fvets.2022.979794

Publication

ISSN: 2297-1769
NlmUniqueID: 101666658
Country: Switzerland
Language: English
Volume: 9
Pages: 979794
PII: 979794

Researcher Affiliations

Ebner, Lisa
  • Department of Clinical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis.
  • College of Veterinary Medicine, Lincoln Memorial University, Harrogate, TN, United States.
O, Odette
  • Department of Clinical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis.
  • SAGE Veterinary Centers, Dublin, CA, United States.
Simon, Bradley
  • Department of Clinical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis.
  • Department of Small Animal Clinical Sciences, College of Veterinary Medicine and Biomedical Sciences, Texas A&M University, College Station, TX, United States.
Lizarraga, Ignacio
  • Department of Biomedical Sciences, Ross University School of Veterinary Medicine, Basseterre, Saint Kitts and Nevis.
Smith, Joe
  • Department of Large Animal Clinical Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States.
  • Department of Biomedical Sciences, College of Veterinary Medicine, Iowa State University, Ames, IA, United States.
Cox, Sherry
  • Department of Biomedical and Diagnostic Sciences, College of Veterinary Medicine, University of Tennessee, Knoxville, Knoxville, TN, United States.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

This article includes 34 references
  1. Upjohn MM, Pfeiffer DU, Verheyen KL. Helping working Equidae and their owners in developing countries: monitoring and evaluation of evidence-based interventions.. Vet J 2014 Feb;199(2):210-6.
    doi: 10.1016/j.tvjl.2013.09.065pubmed: 24269105google scholar: lookup
  2. Norris SL, Little HA, Ryding J, Raw Z. Global donkey and mule populations: Figures and trends.. PLoS One 2021;16(2):e0247830.
  3. The Donkey Sanctuary Knowledge Advice. (2022). Available online at: http://www.thedonkeysanctuary.org.uk/donkey-assisted-therapy (accessed May 30, 2022).
  4. Lizarraga I, Janovyak E. Comparison of the mechanical hypoalgesic effects of five α2-adrenoceptor agonists in donkeys.. Vet Rec 2013 Sep 28;173(12):294.
    doi: 10.1136/vr.101684pubmed: 23878192google scholar: lookup
  5. Senior JM. Not small horses: improving treatments for donkeys.. Vet Rec 2013 Sep 28;173(12):292-3.
    doi: 10.1136/vr.f5646pubmed: 24077145google scholar: lookup
  6. Mealey KL, Matthews NS, Peck KE, Burchfield ML, Bennett BS, Taylor TS. Pharmacokinetics of R(-) and S(+) carprofen after administration of racemic carprofen in donkeys and horses.. Am J Vet Res 2004 Nov;65(11):1479-82.
    doi: 10.2460/ajvr.2004.65.1479pubmed: 15566084google scholar: lookup
  7. Sinclair MD, Mealey KL, Matthews NS, Peck KE, Taylor TS, Bennett BS. Comparative pharmacokinetics of meloxicam in clinically normal horses and donkeys.. Am J Vet Res 2006 Jun;67(6):1082-5.
    doi: 10.2460/ajvr.67.6.1082pubmed: 16740106google scholar: lookup
  8. Matthews NS, Peck KE, Mealey KL, Taylor TS, Ray AC. Pharmacokinetics and cardiopulmonary effects of guaifenesin in donkeys.. J Vet Pharmacol Ther 1997 Dec;20(6):442-6.
  9. Lizarraga I, Sumano H, Brumbaugh G. Pharmacological and pharmacokinetic differences between donkeys and horses. Equine Vet Educ (2004) 16:102–12.
  10. Mendoza FJ, Perez-Ecija A, Toribio RE. Clinical Pharmacology in Donkeys and Mules.. Vet Clin North Am Equine Pract 2019 Dec;35(3):589-606.
    doi: 10.1016/j.cveq.2019.08.011pubmed: 31587974google scholar: lookup
  11. Chapuis RJJ, Smith JS, French HM, Toka FN, Peterson EW, Little EL. Nonlinear Mixed-Effect Pharmacokinetic Modeling and Distribution of Doxycycline in Healthy Female Donkeys after Multiple Intragastric Dosing-Preliminary Investigation.. Animals (Basel) 2021 Jul 9;11(7).
    doi: 10.3390/ani11072047pmc: PMC8300337pubmed: 34359175google scholar: lookup
  12. KuKanich B, Wiese A. Opioids. Veterinary anesthesia and analgesia: The Fifth Edition of Lumb and Jones Ames, IA: Wiley-Blackwell. (2015). p. 220–1.
  13. Kalpravidh M, Lumb WV, Wright M, Heath RB. Analgesic effects of butorphanol in horses: dose-response studies.. Am J Vet Res 1984 Feb;45(2):211-6.
  14. Sellon DC, Monroe VL, Roberts MC, Papich MG. Pharmacokinetics and adverse effects of butorphanol administered by single intravenous injection or continuous intravenous infusion in horses.. Am J Vet Res 2001 Feb;62(2):183-9.
    doi: 10.2460/ajvr.2001.62.183pubmed: 11212025google scholar: lookup
  15. Sellon DC, Papich MG, Palmer L, Remund B. Pharmacokinetics of butorphanol in horses after intramuscular injection.. J Vet Pharmacol Ther 2009 Feb;32(1):62-5.
  16. Chiavaccini L, Claude AK, Lee JH, Ross MK, Meyer RE, Langston VC. Pharmacokinetics and pharmacodynamics comparison between subcutaneous and intravenous butorphanol administration in horses.. J Vet Pharmacol Ther 2015 Aug;38(4):365-74.
    doi: 10.1111/jvp.12191pubmed: 25484250google scholar: lookup
  17. Arguedas MG, Hines MT, Papich MG, Farnsworth KD, Sellon DC. Pharmacokinetics of butorphanol and evaluation of physiologic and behavioral effects after intravenous and intramuscular administration to neonatal foals.. J Vet Intern Med 2008 Nov-Dec;22(6):1417-26.
  18. Paine SW, Bright J, Scarth JP, Hincks PR, Pearce CM, Hannan C, Machnik M, Hillyer L. The intravenous pharmacokinetics of butorphanol and detomidine dosed in combination compared with individual dose administrations to exercised horses.. J Vet Pharmacol Ther 2020 Mar;43(2):162-170.
    doi: 10.1111/jvp.12838pubmed: 32012314google scholar: lookup
  19. Joubert KE, Briggs P, Gerber D, Gottschalk RG. The sedative and analgesic effects of detomidine-butorphanol and detomidine alone in donkeys.. J S Afr Vet Assoc 1999 Sep;70(3):112-8.
    doi: 10.4102/jsava.v70i3.769pubmed: 10852680google scholar: lookup
  20. Lizarraga I, Castillo-Alcala F. Sedative and mechanical hypoalgesic effects of butorphanol in xylazine-premedicated donkeys.. Equine Vet J 2015 May;47(3):308-12.
    doi: 10.1111/evj.12274pubmed: 24735190google scholar: lookup
  21. Matthews NS, Taylor TS, Hartsfield SM, Williams JD. A comparison of injectable anaesthetic regimens in Mammoth asses.. Equine Vet J Suppl 1992 Feb;(11):37-40.
  22. Matthews NS, Taylor TS, Skrobarcek CL, Williams JD. A comparison of injectable anaesthetic regimens in mules.. Equine Vet J Suppl 1992 Feb;(11):34-6.
  23. Robertson JT, Muir WW, Sams R. Cardiopulmonary effects of butorphanol tartrate in horses.. Am J Vet Res 1981 Jan;42(1):41-4.
    pubmed: 7224316
  24. Yarbrough J, Greenacre C, Cox S. Determination of butorphanol using high performance liquid chromatography in small volume plasma samples. J Liq Chromatogr Relat Technol (2014) 37:1270–7.
  25. Yamaoka K, Nakagawa T, Uno T. Application of Akaike's information criterion (AIC) in the evaluation of linear pharmacokinetic equations.. J Pharmacokinet Biopharm 1978 Apr;6(2):165-75.
    doi: 10.1007/BF01117450pubmed: 671222google scholar: lookup
  26. Toutain PL, Bousquet-Mélou A. Plasma clearance.. J Vet Pharmacol Ther 2004 Dec;27(6):415-25.
  27. Smith JS, Marmulak TL, Angelos JA, Lin Z, Rowe JD, Carlson JL, Shelver WL, Lee EA, Tell LA. Pharmacokinetic Parameters and Estimated Milk Withdrawal Intervals for Domestic Goats (Capra Aegagrus Hircus) After Administration of Single and Multiple Intravenous and Subcutaneous Doses of Flunixin Meglumine.. Front Vet Sci 2020;7:213.
    doi: 10.3389/fvets.2020.00213pmc: PMC7248982pubmed: 32509803google scholar: lookup
  28. Smith JS, Coetzee JF, Fisher IWG, Borts DJ, Mochel JP. Pharmacokinetics of fentanyl citrate and norfentanyl in Holstein calves and effect of analytical performances on fentanyl parameter estimation.. J Vet Pharmacol Ther 2018 Aug;41(4):555-561.
    doi: 10.1111/jvp.12501pubmed: 29603262google scholar: lookup
  29. Price G, Patel DA. Drug Bioavailability.. 2023 Jan;.
    pubmed: 32496732
  30. Gordon E, Dirikolu L, Liu CC, Ulanov AV, Li Z, Welborn M, Armstrong C, Vallotton D, Keeton S, Camlic S, Scully CM. Pharmacokinetic profiles of three dose rates of morphine sulfate following single intravenous, intramuscular, and subcutaneous administration in the goat.. J Vet Pharmacol Ther 2022 Jan;45(1):107-116.
    doi: 10.1111/jvp.13011pubmed: 34494277google scholar: lookup
  31. Uhrig SR, Papich MG, KuKanich B, Mama KR, Wagner AE, Chapman PL, Hellyer PW. Pharmacokinetics and pharmacodynamics of morphine in llamas.. Am J Vet Res 2007 Jan;68(1):25-34.
    doi: 10.2460/ajvr.68.1.25pubmed: 17199415google scholar: lookup
  32. Barnhart MD, Hubbell JA, Muir WW, Sams RA, Bednarski RM. Pharmacokinetics, pharmacodynamics, and analgesic effects of morphine after rectal, intramuscular, and intravenous administration in dogs.. Am J Vet Res 2000 Jan;61(1):24-8.
    doi: 10.2460/ajvr.2000.61.24pubmed: 10630773google scholar: lookup
  33. Riviere JE, Chittenden J. Study design and data analysis. Comparative Pharmacokinetics 2 ed. Ames, IA: Wiley Blackwell (2011). p. 311.
  34. Bon C, Toutain PL, Concordet D, Gehring R, Martin-Jimenez T, Smith J, Pelligand L, Martinez M, Whittem T, Riviere JE, Mochel JP. Mathematical modeling and simulation in animal health. Part III: Using nonlinear mixed-effects to characterize and quantify variability in drug pharmacokinetics.. J Vet Pharmacol Ther 2018 Apr;41(2):171-183.
    doi: 10.1111/jvp.12473pubmed: 29226975google scholar: lookup

Citations

This article has been cited 0 times.